Company Overview
Elicio Therapeutics, Inc. operates as a clinical-stage biotechnology company focused on developing immunotherapies designed for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine currently in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog-positive cancers. The company is categorized within the Healthcare sector and the Biotechnology industry, positioning it among entities that rely heavily on research and development to bring novel therapeutics to market rather than established commercial sales pipelines. With a market capitalization of $201.62M and an employee count of 33, Elicio Therapeutics presents the financial profile typical of a pre-revenue biotechnology firm where valuation is driven by intellectual property potential rather than current profitability. The absence of annual revenue in the financial data reflects the company's stage in development, where capital is primarily allocated to advancing clinical trials rather than generating commercial income, indicating a high-risk, high-reward investment profile common in early-phase biotech.
Financial Health
The company reports no revenue for the trailing twelve months, resulting in a net income of $-39,571,000 and an EBITDA of $-37,510,000. The gap between the non-existent revenue and the significant negative net income reveals a cost structure entirely dependent on operational expenses related to clinical trial execution, research, and general corporate overhead. This financial structure is characteristic of clinical-stage biotechnology firms that incur substantial costs to advance their product candidates through regulatory pathways before any commercial launch. Free cash flow stands at $-21,666,376, indicating that the company is consuming cash reserves to fund its operations and development activities, which limits immediate financial flexibility but is a necessary condition for progressing its pipeline. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that accurately represents a company with no revenue stream yet to calculate profitability percentages. The balance sheet shows cash holdings of $18.56M against total debt of $14.51M, with a debt-to-equity ratio of 887.04, suggesting a leveraged position relative to equity but one that is typical for asset-light biotechnology companies with minimal interest obligations. The current ratio of 2.38 indicates that the company possesses sufficient liquid assets to cover its short-term liabilities, providing a buffer against immediate liquidity crises despite the ongoing cash burn. Return on equity is N/A due to the lack of net income, while return on assets is -87.2%, highlighting the significant dilution of asset value by losses incurred during the development phase.
Valuation Assessment
The P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is -7.83, a metric that implies the market is pricing in future earnings expectations that are currently speculative and unproven. The price-to-book ratio is 119.13, which indicates a substantial market premium over the company's book value, reflecting investor optimism regarding the potential success of the ELI-002 vaccine candidate and the value of its intellectual property. The price-to-sales ratio is N/A because the company has not yet generated commercial sales, and the EV/EBITDA stands at -5.27, further emphasizing that traditional valuation multiples based on profitability are not applicable at this stage of the company's lifecycle. The stock has traded between a 52-week low of $4.60 and a 52-week high of $14.93, with the current price situated within this range but subject to significant fluctuation based on clinical trial data releases. The beta of 1.68 signifies that the stock's price volatility is substantially higher than that of the broader market, meaning the asset will likely experience larger swings in value during periods of market stress or growth.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both N/A, as the company has not yet achieved commercial revenue generation to calculate percentage growth rates. In the absence of revenue, there is no earnings growth to compare against revenue growth, and the company's financial trajectory is currently defined by the expenditure required to complete its clinical development program rather than top-line expansion. Elicio Therapeutics does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all available cash to reinvest into its research and development efforts rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage biotechnology firms that prioritize advancing their product pipelines over providing immediate income returns to investors. The overall growth and income profile is characterized by a focus on capital allocation toward clinical milestones rather than dividend payments or revenue expansion, with all financial metrics reflecting the pre-commercial nature of the business.